Answers are grounded in this paper and cite their sources.
Research shows drug development enhances antihormonal treatment efficacy in breast cancer by reducing toxicity.
The field of antihormonal therapy of cancer is advancing at a rapid pace and continues to produce drugs which interfere either with hormone production or action. Newly developed compounds include: luteinizing hormone-releasing hormone (LH-RH) analogues, which reversibly suppress ovarian activity in premenopausal women; aromatase and sulphatase inhibitors, which interfere with extra-ovarian oestrogen production; and novel hormone antagonists, which exert their actions through the cellular hormone receptors present in some breast cancers. Present directions in drug development programmes favour both the production of drugs with conceived improvements in their biological profile and also those with improved potency and reduced toxicity. The latter characteristic aids the use of antihormone procedures at early stages of cancer development, a trend which is currently promoting a reduction in breast cancer mortality rates.
No takes yet. Share an insight, caveat, or question.
R. Nicholson (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: